BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer.

PLoS One · 2016 · PMC5158199 · PMID 27977696

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The BRCAness group had a significantly shorter recurrence-free survival (RFS) compared with the non-BRCAness group ( P = 0.04) and had a shorter overall survival (OS) although this did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.